The authors were able to confirm that B2M mutated MMR-d cancers derived clinical benefit from treatment with anti-PD-1 therapy, which demonstrates that in tumors that lack MHC class I antigen presentation, other immune effectors such as γδ T cells can mediate response to PD-1 blockade. This evidence concerns the gene B2M and cancer.